Arg1912
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Di-methylation Site Page: > Arg1912  -  MED12 (human)

Site Information
VPQGQrLrQQLQQSQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15381293

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 2 , 3 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
breast cancer ( 1 ) , colorectal cancer ( 2 , 3 ) , colorectal carcinoma ( 2 , 3 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on MED12:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
transcription, inhibited ( 1 )
Induce interaction with:
DNA ( 1 )

References 

1

Wang L, et al. (2015) MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs. Sci Adv 1, e1500463
26601288   Curated Info

2

Possemato A (2010) CST Curation Set: 9390; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

3

Possemato A (2010) CST Curation Set: 9391; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info